Despite lowered Q1 earnings guidance, Biogen Inc. (NASDAQ:BIIB) continues to pique investment interests. New product growth outpaces the declining MS Franchise and the company is at the brink of a turnaround. Alzheimer's treatment continues to be a crucial focus with BIIB080 receiving FDA Fast Track Designation. Graham Capital Management, Lazard Asset Management and other institutions accumulate Biogen Inc. shares, recognizing its potential. Biogen performed well in Q1 due to the strength of rare disease drugs and has secured its place amongst small-cap healthcare stocks that hedge funds are buying.
While some financial institutions including Mizuho lowered their price target, others like JP Morgan have maintained their rating despite cutting the price target. Biogen has seen robust growth in revenue, with new products boosting this surge. However, concerns remain as Biogen lowered their profit outlook post a deal for an epilepsy drug and quarterly earnings slightly fell behind estimates. Nevertheless, Biogen remains confident and is primed for its readout of a major programme slated for mid-2026.
Biogen BIIB News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 17 May 2025 18:36:38 GMT - Rating 2 - Innovation 6 - Information 4 - Rumor -3
